|
Citation
|
Kawamura N, Shinoda K, Sato H, Sasaki K, Suzuki M, Yamaki K, Fujimori T, Yamamoto H, Osei-Hyiaman D, Ohashi Y. Psychiatry Clin. Neurosci. 2018; 72(5): 349-361. |
|
Abstract
|
AIM: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD).
METHODS: Psychiatric assessments were made with the Structured Clinical Interview for Diagnosis. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis-mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker.
RESULTS: Among 23 metabolites significantly lower in MDD group than healthy control, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD were checked in independent clinical sample sets. An ion-chromatography-fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non-MDD subjects. The area under the curve of the receiver operating characteristic (AUC) was 0.92, with sensitivity/specificity greater than 88%, at a cut-off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non-MDD subjects, the AUC was 0.89, with sensitivity/specificity of 86% and 100% respectively at a cut-off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation.
CONCLUSION: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.
This article is protected by copyright. All rights reserved.
Language: en |